Cowen & Co. analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD) today and set a price target of $66.00. The company’s shares closed last Monday at $38.06.
According to TipRanks.com, Baral is a 2-star analyst with an average return of -1.0% and a 31.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals with a $58.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $53.70 and a one-year low of $21.56. Currently, ACADIA Pharmaceuticals has an average volume of 1.39M.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACAD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
